Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim for Refractory Aplastic Anemia After Radiotherapy
NCT06516484Phase 4Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jul 2024
- Primary completion
- Jul 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of romiplostim in aplastic anemia, sponsored by Peking Union Medical College Hospital. Primary endpoints: Overall Response Rate at 6 months and Complete Response Rate at 6 months. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
romiplostim
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on NCT06516484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06516484.